Toronto, Ontario, Canada Genesys Capital is the famous VC, which was founded in 2000. The company was established in North America in Canada. The leading representative office of defined VC is situated in the Toronto.
This organization was formed by Damian Lamb, Kelly Holman. The overall number of key employees were 4.
Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. We can highlight the next thriving fund investment areas, such as Medical Device, Medical. Among the most popular portfolio startups of the fund, we may highlight Fusion Pharmaceuticals, Tioga Pharmaceuticals, NeurAxon. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Canada. The fund has exact preference in some founders of portfolio startups. If startup sums 3 of the founder, the chance for it to be financed is low.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Genesys Capital, startups are often financed by Adams Street Partners, TPG Biotech, PathoCapital. The meaningful sponsors for the fund in investment in the same round are Adams Street Partners, TPG Biotech, PathoCapital. In the next rounds fund is usually obtained by OrbiMed, Adams Street Partners, Varian Medical Systems.
Considering the real fund results, this VC is 10 percentage points less often commits exit comparing to other organizations. Opposing the other organizations, this Genesys Capital works on 14 percentage points less the average amount of lead investments. The high activity for fund was in 2018. Despite it in 2019 the fund had an activity. The top amount of exits for fund were in 2015. The fund is constantly included in less than 2 deals per year. The usual things for fund are deals in the range of 10 - 50 millions dollars.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Aflac | Columbus, Georgia, United States |
| Allstate Strategic Ventures | Illinois, Northbrook, United States |
| Altatech | France, Montbonnot-saint-martin, Rhone-Alpes |
| Analog Devices | Massachusetts, Norwood, United States |
| BayStartUP | Bavaria, Germany, Nuremberg |
| DIP Capital | England, London, United Kingdom |
| High Rise Ventures | Berlin, Berlin, Germany |
| Ipanema Technologies | Courceboeufs, France, Pays de la Loire |
| Joyance Partners | California, San Francisco, United States |
| Leksell Social Ventures | - |
| Neoforma | California, San Jose, United States |
| Quantum Leap for Technology Co. | - |
| Shanghai Shanrui Investment | China, Shanghai |
| Shanghai Xuntian Investment | China, Shanghai |
| Shenzhen Qianhai Zhongyinhui Investment Management | China, Guangdong, Shenzhen |
| Silicom Ventures | California, Los Altos, United States |
| Steinbeis | - |
| Vigo Activo | Galicia, Nigrán, Spain |
| Wensu Investment | - |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Flosonics | $20M | 19 Mar 2024 | Greater Sudbury, Ontario, Canada | ||
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Veralox Therapeutics | $16M | 16 Jun 2021 | Frederick, Maryland, United States | ||
Giiant Pharma | $11M | 21 May 2021 | Montréal, Quebec, Canada | ||
Inversago Pharma | $35M | 08 Sep 2020 | Montreal, Quebec | ||
IDbyDNA | $20M | 29 Jan 2020 | California, United States | ||
EBT Medical | $10M | 19 Nov 2019 | Ontario | ||
Fusion Pharmaceuticals | $105M | 01 Apr 2019 | Hamilton, Ontario, Canada | ||
Inversago Pharma | $7M | 25 Jul 2018 | Montreal, Quebec, Canada |
– Giiant Pharma inc. announced that is closed an additional financing of $750,000 from AQC Capital and $500,000 from CQDM for a total of $1.25 million.
– The preclinical-stage biotech Company’s also closed a Seed round of $13.5 million, co-led by Amplitude Ventures and Genesys Capital.
– This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
– Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. The team is also in active discussions with potential partners to expand its pipeline of precisely delivered drug therapeutics for gastrointestinal disease.
– Veralox is a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, closed a $16.6m Series A financing.
– The round was led by Hatteras Venture Partners with participation from Genesys Capital, Point Field Partners and Alexandria Venture Investments as well as support from previous investors Sanofi Ventures, JDRF T1D Fund, Maryland Momentum Fund, VTC Innovation Fund and TEDCO.
– The new investment will be used to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Flosonics | $20M | 19 Mar 2024 | Greater Sudbury, Ontario, Canada | ||
Inversago Pharma | $75M | 17 Oct 2022 | Montreal, Quebec, Canada | ||
Veralox Therapeutics | $16M | 16 Jun 2021 | Frederick, Maryland, United States | ||
Giiant Pharma | $11M | 21 May 2021 | Montréal, Quebec, Canada | ||
Inversago Pharma | $35M | 08 Sep 2020 | Montreal, Quebec | ||
IDbyDNA | $20M | 29 Jan 2020 | California, United States | ||
EBT Medical | $10M | 19 Nov 2019 | Ontario | ||
Fusion Pharmaceuticals | $105M | 01 Apr 2019 | Hamilton, Ontario, Canada | ||
Inversago Pharma | $7M | 25 Jul 2018 | Montreal, Quebec, Canada |
